Aug 02, 2023 |
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
|
|
Jul 28, 2023 |
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
|
|
Jun 26, 2023 |
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
|
|
Jun 22, 2023 |
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
|
|
May 25, 2023 |
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
|
|
May 19, 2023 |
Adamis Pharmaceuticals Announces Reverse Stock Split
|
|
May 15, 2023 |
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
|
|
May 08, 2023 |
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
|
|
Mar 16, 2023 |
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
|
|
Mar 14, 2023 |
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
|
|